Shell Asset Management Co. acquired a new stake in CryoLife, Inc. (NYSE:CRY) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 92,405 shares of the medical equipment provider’s stock, valued at approximately $912,000. Shell Asset Management Co. owned approximately 0.28% of CryoLife as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue increased its position in shares of CryoLife by 80.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after buying an additional 2,407 shares in the last quarter. First Mercantile Trust Co. increased its position in shares of CryoLife by 5.6% in the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after buying an additional 291 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of CryoLife by 3.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 190 shares in the last quarter. Creative Planning increased its position in shares of CryoLife by 3.0% in the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after buying an additional 200 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of CryoLife by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 1,041 shares in the last quarter. Institutional investors and hedge funds own 69.01% of the company’s stock.

A number of research firms recently commented on CRY. BidaskClub cut shares of CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. TheStreet cut CryoLife from a “b” rating to a “c+” rating in a report on Monday. Zacks Investment Research upgraded CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Canaccord Genuity reiterated a “buy” rating and set a $25.00 target price on shares of CryoLife in a report on Monday, October 9th. Finally, Lake Street Capital increased their target price on CryoLife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $23.63.

In other CryoLife news, CEO James P. Mackin sold 125,000 shares of CryoLife stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total value of $2,751,250.00. Following the completion of the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO James P. Mackin sold 43,050 shares of CryoLife stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,800,633.91. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 171,050 shares of company stock valued at $3,769,825. Insiders own 6.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Shell Asset Management Co. Takes Position in CryoLife, Inc. (CRY)” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/11/02/shell-asset-management-co-takes-position-in-cryolife-inc-cry.html.

CryoLife (NYSE:CRY) last posted its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. CryoLife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million during the quarter, compared to the consensus estimate of $44.60 million. During the same period in the previous year, the firm posted $0.13 earnings per share. The business’s revenue was down 2.9% compared to the same quarter last year.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.